Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Risk factors

Topic: Risk, prevention and care in population studies

Plain-language summary

Abstract Background With population aging, underdiagnosis of Alzheimer's disease and related dementias (ADRD) may result to missed opportunities to improve health and may stem from insufficient diagnostic service availability. Result Average county‐level ADRD prevalence was 11.06% across the pre‐expansion period and 7.15% post‐expansion. ADRD prevalence was 2.48% higher in counties with broadband versus counties without broadband post‐expansion compared to pre‐expansion (95% Confidence Interval (CI): 1.01, 1.04; Figure). While improvements in ADRD detection may have occurred in counties with broadband following the expansion, the substantial decrease in ADRD prevalence overall is likely a consequence of the COVID‐19 pandemic and should be explored further.

What this study adds

Evidence grade: Low

This study looked at county-level dementia diagnosis rates around the 2020 Medicare telehealth expansion and found overall prevalence fell, likely because of the COVID-19 pandemic. Reported effect size: 11.06%; 7.15%; 70.35%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Rajczyk, J. I., Burke, J. F., & Wing, J. J. (2025). Effect of the 2020 CMS telehealth expansion on diagnostic prevalence of Alzheimer's disease and related dementias. Alzheimer s & Dementia. https://doi.org/10.1002/alz70860_105857

Vancouver

Rajczyk JI, Burke JF, Wing JJ. Effect of the 2020 CMS telehealth expansion on diagnostic prevalence of Alzheimer's disease and related dementias. Alzheimer s & Dementia. 2025. doi:10.1002/alz70860_105857. PMID: 41435157.

BibTeX

@article{rajczyk2025-41435157,
  author  = {Rajczyk, Jenna I. and Burke, James Francis and Wing, Jeffrey J.},
  title   = {{Effect of the 2020 CMS telehealth expansion on diagnostic prevalence of Alzheimer's disease and related dementias}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70860_105857},
  pmid    = {41435157},
  url     = {https://doi.org/10.1002/alz70860_105857}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This study looked at county-level dementia diagnosis rates around the 2020 Medicare telehealth expansion and found overall prevalence fell, likely because of the COVID-19 pandemic. It is about diagnosis and detection, not about treating, curing or preventing Alzheimer's disease.

Study details

How this study scored 33/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 2 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 33 of 100.33 of 100 points earned67 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 3 year(s) since 2025
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Jeffrey J. Wing: h-index 24 (OpenAlex, whole career)
Institution's track record 1 / 3 The Ohio State University: institution h-index 1,378 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41435157)
Free to read 2 / 2 Free to read
Total 33 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Risk factors from nearby years

Also tagged “prevalence”

1,225 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,225 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Risk factors

See all studies in Risk factors →